A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial)
Masayuki Takeda(Nara Medical University Hospital), Masahide Ota(Nara Medical University), Eiji Iwama(Kyushu University), Shunichi Sugawara(Sendai Kousei Hospital), Takehito Shukuya(Juntendo University), Shigeki Umemura(National Cancer Center Hospital East), Hiroshi Tanaka(Niigata Cancer Center Hospital), Masahide Oki(Nagoya Medical Center), Takayuki Takahama(Kindai University), Takeshi Masuda(Hiroshima University Hospital), Naoyuki Nogami(Ehime University), Mototsugu Shimokawa(Yamaguchi University)
Cited by 5
Abstract
Related Papers
No related papers found
Powered by citation graph analysis